Foamix Pharmaceuticals, Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a significant shareholder of the Company, intends to vote in favor of the proposed merger with Menlo Therapeutics at the Company’s upcoming extraordinary general meeting of shareholders. OrbiMed expressed its support for the transaction in a press release issued on January 16, 2020. Perceptive Advisors LLC, the Company’s largest shareholder, previously signed a voting agreement on November 10, 2019 to vote its Foamix shares in favor of the merger at the meeting.
“We are delighted to have the support of both OrbiMed and Perceptive Advisors for our transformative transaction with Menlo Therapeutics,” said David Domzalski, Chief Executive Officer of Foamix. “Having the support of two of our largest shareholders is a significant step toward completing the transaction.”
Source: BioSpace